Icosavax, Inc.

Icosavax, Inc.

A biotechnology company in Washington that focuses on developing safe and effective vaccines against infectious diseases.

Icosavax is a biotechnology company in Washington that focuses on developing safe and effective vaccines against infectious diseases. Founded 2017 in Seattle, Washington, United States by David Baker Ph.D, Neil King, Adam Simpson JD, it invests in early stage ventures. It is a developer of computationally designed virus-like particle vaccines that are intended to reduce serious infectious diseases, including Respiratory Syncytial Virus. The vaccine is being developed to protect older people from respiratory syncytial virus (RSV) diseases. The company believes that science and technology can and will continue to improve public health and that preventing infection is preferable to treating illness.

Timeline

2017
Founded

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Icosavax funding round, October 2019
52,000,000
October 2019
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

David Baker

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.